{"groups":[{"description":"Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.\n\ntherapeutic allogeneic lymphocytes: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"FG000","title":"Treatment (DLI)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"17"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"12"}],"type":"Relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"GVHD"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Graft Failure"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"77"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"36"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"41"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}